In a groundbreaking development, Israeli medical imaging startup Techsomed has introduced a pioneering AI technology set to revolutionize the treatment landscape for liver cancer patients worldwide.
With their innovative solution, BioTraceIO, physicians can perform thermal ablation therapy with unprecedented precision and real-time guidance, ushering in a new era of minimally invasive treatment.
Overcoming challenges with cutting-edge AI
Traditional thermal ablation therapy, a minimally invasive procedure for small liver tumors, has long been hindered by a critical limitation – the inability of interventional radiologists to visualize the tumor accurately during the procedure. This drawback often resulted in imprecise targeting, leading to suboptimal patient outcomes.
However, Techsomed’s visionary team, leveraging their diverse backgrounds in defense, aviation, and semiconductor industries, embarked on a mission to harness the power of AI to overcome this challenge.
After seven years of intensive research and a significant investment of $25 million, Techsomed successfully developed BioTraceIO. This sophisticated AI system utilizes advanced algorithms, originally designed for stabilizing missiles, to interpret ultrasound images and provide real-time insights into the tumor’s response to ablation therapy.
By deciphering the chaotic phenomenon of gas bubble formation during the procedure, BioTraceIO offers physicians a clear, high-quality ablation map, enabling precise tumor targeting and minimizing damage to healthy tissue.
Game-changing benefits for patients
The introduction of BioTraceIO marks a paradigm shift in liver cancer treatment, offering patients unparalleled benefits. Unlike conventional surgery or chemotherapy, thermal ablation therapy with BioTraceIO requires minimal hospitalization and offers rapid recovery, with patients often returning home on the same day.
Moreover, the procedure, performed under local anesthesia, eliminates the risk of side effects associated with traditional treatments, providing patients with a safer and more comfortable experience.
With its ability to predict tumor response over the next 24 hours, BioTraceIO empowers physicians to optimize treatment outcomes and enhance patient care. This transformative technology improves the efficacy of thermal ablation therapy and opens doors for its widespread adoption as a first-line curative treatment for liver tumors.
Expanding possibilities beyond liver cancer
While BioTraceIO initially targets liver tumors, Techsomed envisions extending its impact to a broader spectrum of solid tumors and non-tumor ablation treatments. With plans to develop parallel technologies for kidney, thyroid, cardiac, and chronic pain issues, Techsomed aims to democratize ablation therapy, making high-quality treatment accessible to patients worldwide.
Following successful trials in medical centers across Israel, Japan, and the United States, BioTraceIO received De Novo clearance from the US Food and Drug Administration (FDA), solidifying its status as a pioneering technology in the medical field. With impending integration into hospitals worldwide, Techsomed anticipates rapid market penetration and significant financial success.
